Proximal renal tubular acidosis
| Proximal renal tubular acidosis | |
|---|---|
| Synonyms | Type 2 renal tubular acidosis |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Polyuria, polydipsia, muscle weakness, bone pain |
| Complications | Growth retardation, osteomalacia, nephrocalcinosis |
| Onset | Childhood or adulthood |
| Duration | Chronic |
| Types | N/A |
| Causes | Genetic disorders, autoimmune diseases, toxins, medications |
| Risks | Family history, autoimmune conditions |
| Diagnosis | Blood test, urinalysis, ammonium chloride loading test |
| Differential diagnosis | Distal renal tubular acidosis, Fanconi syndrome, chronic kidney disease |
| Prevention | N/A |
| Treatment | Bicarbonate therapy, potassium supplements, thiazide diuretics |
| Medication | N/A |
| Prognosis | Variable, depends on underlying cause and treatment |
| Frequency | Rare |
| Deaths | N/A |
Proximal Renal Tubular Acidosis
Proximal renal tubular acidosis (pRTA) is a type of renal tubular acidosis (RTA) characterized by a defect in the reabsorption of bicarbonate (HCO₃⁻) in the proximal tubule of the nephron. This condition leads to a decrease in blood bicarbonate levels, resulting in metabolic acidosis. pRTA is also known as Type 2 RTA.
Pathophysiology[edit]
In pRTA, the proximal tubule of the nephron fails to reabsorb bicarbonate efficiently. Normally, the proximal tubule reabsorbs about 80-90% of the filtered bicarbonate. In pRTA, this reabsorption is impaired, leading to bicarbonate wasting in the urine and a subsequent decrease in blood bicarbonate levels. This results in a non-anion gap metabolic acidosis. The defect in bicarbonate reabsorption can be due to various causes, including genetic mutations affecting transporters, acquired conditions, or as part of a generalized proximal tubular dysfunction known as Fanconi syndrome.
Causes[edit]
Proximal RTA can be caused by:
- Genetic mutations: Mutations in genes encoding for bicarbonate transporters, such as SLC4A4, can lead to inherited forms of pRTA.
- Acquired conditions: Conditions such as multiple myeloma, certain medications (e.g., carbonic anhydrase inhibitors), and heavy metal poisoning can cause pRTA.
- Fanconi syndrome: pRTA is often a component of Fanconi syndrome, which involves generalized dysfunction of the proximal tubule, leading to the loss of multiple substances in the urine, including glucose, amino acids, phosphate, and bicarbonate.
Clinical Features[edit]
Patients with pRTA may present with:
- Metabolic acidosis: Due to bicarbonate loss, patients develop a non-anion gap metabolic acidosis.
- Hypokalemia: Potassium wasting can occur, leading to low blood potassium levels.
- Growth retardation: In children, chronic acidosis can lead to growth retardation.
- Bone demineralization: Chronic acidosis can lead to bone demineralization and osteomalacia.
Diagnosis[edit]
The diagnosis of pRTA involves:
- Blood tests: Showing metabolic acidosis with normal anion gap and low bicarbonate levels.
- Urine tests: Demonstrating bicarbonate wasting in the urine, especially after bicarbonate loading.
- Genetic testing: In cases of suspected hereditary pRTA, genetic testing may identify mutations in relevant genes.
Treatment[edit]
The primary treatment for pRTA involves:
- Alkali therapy: Oral bicarbonate or citrate supplements are used to correct acidosis.
- Potassium supplementation: If hypokalemia is present, potassium supplements may be necessary.
- Treating underlying causes: Addressing any underlying conditions contributing to pRTA, such as discontinuing offending drugs or treating associated diseases.
Prognosis[edit]
The prognosis of pRTA depends on the underlying cause and the effectiveness of treatment. With appropriate management, many patients can maintain normal growth and development, although some may experience complications related to chronic acidosis.
Also see[edit]
| Physiology of the kidneys and acid–base physiology | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian